Jinhua Drug Administration Visits Pharmaceutical Companies
Release time:
2022-10-08
News from our newspaper 9# February 15 , Lu Saihua, deputy director of Jinhua Municipal Drug Administration, and his party went to Jinhua Pharmaceutical Company to visit and learn about the implementation of the "Administrative Licensing Regulations for Pharmaceutical Wholesale Enterprises in Zhejiang Province (Trial)", what kind of support and help the enterprise needs from the government, and the operation of the enterprise in the first half of the year when the new crown epidemic occurred frequently in Jinhua.
In order to strengthen the access management of pharmaceutical trading enterprises and promote the standardized and orderly development of the pharmaceutical circulation field, the Zhejiang Provincial Drug Administration has formulated the "Administrative Licensing Regulations for Pharmaceutical Wholesale Enterprises in Zhejiang Province (Trial)". According to the requirements of the regulations, Pharmaceutical wholesale companies must meet the requirements of the regulations on the basis of meeting the relevant requirements of the "Pharmaceutical Business Quality Management Regulations. The "Regulations" will be implemented from 2022 , 9, 1 , of which articles 10 to 16 can be postponed to 2024 , 9 , 1 . At that time, if the drug trading enterprise still does not meet the prescribed requirements, it will no longer accept its application for administrative license. Wu Weisheng, general manager of the pharmaceutical company, introduced the operation of the pharmaceutical company in the first half of the year, and the storage and distribution of epidemic prevention and control materials for the government. Lu Saihua fully affirmed the efforts and contributions made by the pharmaceutical companies. He asked the pharmaceutical companies to put them in place in strict accordance with the provisions of the "Regulations" in the next two years, and to prepare for the implementation of the new logistics standards at the end of the year. He also suggested that the pharmaceutical companies should make early preparations for the replacement of certificates in 2024
, including staffing, equipment updates, system replacement and other aspects of comprehensive consideration, long-term planning. Lu Saihua also pointed out that as an old enterprise, the pharmaceutical company has an aging personnel structure and a heavy burden on the enterprise. However, the management team should not have the mentality of complaining and carrying the burden. It is necessary to strengthen learning, try every means to change the business thinking and innovate the business model, and lead all the staff to create more benefits with a positive attitude, so that the enterprise can radiate new vitality more continuously and stably and make greater contributions to the society. (Fan Tufa)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page